Can a drug duo tame a rare eye cancer that has spread?
NCT ID NCT05308901
First seen Aug 12, 2026 · Last updated Aug 13, 2026 · Updated 1 time
Summary
This trial is testing whether combining two drugs—pembrolizumab and lenvatinib—can help people with metastatic uveal melanoma, a rare eye cancer that has spread to other parts of the body. Participants receive both drugs for up to two years. The study measures how long people live without the cancer growing, whether tumors shrink, and overall survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- A combination of two drugs: pembrolizumab (an immunotherapy that helps the immune system attack cancer cells) and lenvatinib (a targeted therapy that blocks blood vessel growth to tumors).
- What this could lead to
- If this combination works, it could offer a new treatment option for metastatic uveal melanoma, a rare eye cancer with limited therapies.
- What could go wrong
- This is a small, early-phase trial, so results may not be conclusive. The drugs can cause side effects, and the combination may not be more effective than existing options.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MELANOMA, UVEAL are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Providence Portland Medical Center
Portland, Oregon, 97213, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug shrink Hard-to-Treat eye cancer?
- Double immunotherapy plus liver blockade targets eye cancer that spreads
- First-in-Class cancer drug targets Hard-to-Treat tumors
- Engineered immune cells take on Hard-to-Treat melanoma
- Immune cell therapy shows promise against rare eye cancer
- Liver-Directed chemo shows promise for eye cancer metastases